Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelareorep - Oncolytics Biotech

Drug Profile

Pelareorep - Oncolytics Biotech

Alternative Names: AN-1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus - Oncolytics Biotech

Latest Information Update: 02 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolytics Biotech
  • Developer Adlai Nortye; Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; PrECOG; Roche; University of Leeds; University of Southern California
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer; Head and neck cancer
  • Phase II Brain cancer; Colorectal cancer; Fallopian tube cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
  • Phase I/II Anal cancer; Glioma; Multiple myeloma
  • Preclinical Acute myeloid leukaemia
  • No development reported Glioblastoma; Liver cancer; Solid tumours

Most Recent Events

  • 27 Jun 2024 Oncolytics received productive feedback from Type C meeting with the USFDA
  • 09 May 2024 Oncolytics Biotech receives German regulatory and ethics approvals for Pelareorep in Pancreatic cancer
  • 07 May 2024 National Cancer Institute completes a phase-I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02101944)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top